Sankey diagrams can clarify 'evidence attrition': a systematic review and meta-analysis of the effectiveness of rapid diagnostic tests for antimicrobial resistance by Glover, Rebecca E et al.
 
Journal Pre-proof
Sankey diagrams can clarify ‘evidence attrition’: a systematic review
and meta-analysis of the effectiveness of rapid diagnostic tests for
antimicrobial resistance
Rebecca E. Glover , Mustafa Al-Haboubi , Mark P. Petticrew ,




To appear in: Journal of Clinical Epidemiology
Accepted date: 22 November 2021
Please cite this article as: Rebecca E. Glover , Mustafa Al-Haboubi , Mark P. Petticrew ,
Elizabeth Eastmure , Sharon J Peacock , Nicholas Mays , Sankey diagrams can clarify ‘ev-
idence attrition’: a systematic review and meta-analysis of the effectiveness of rapid di-
agnostic tests for antimicrobial resistance, Journal of Clinical Epidemiology (2021), doi:
https://doi.org/10.1016/j.jclinepi.2021.11.032
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.




 We developed a novel method to identify, group, and analyse included studies in a 
systematic review using a Sankey diagram 
 Sankey diagrams can help compare patterns of methodological quality and 
variation in outcomes within primary studies across sectors and topics within a 
review.  They provide a visual way of identifying methodological concerns in the 
evidence included in systematic reviews. 
 We demonstrated this technique in an area where systematic review and meta-
analysis is underused, namely the clinical effectiveness of rapid diagnostic tests 
for bacterial identification and antibiotic susceptibility testing.  
 This is the first systematic review and MA of the effectiveness of RDTs for 
bacterial identification and antibiotic susceptibility testing which shows that, 
despite their widespread use and claims about their value, they do not appear to be 
effective. 
 While there appears to be evidence of reporting bias (publication bias, small study 
effects), the paucity of studies included in our systematic review means that 
Egger‟s test is underpowered so the influence of publication bias on the summary 
estimates is difficult to determine.  
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To demonstrate, using the example of a new systematic review of rapid diagnostic tests, how 
Sankey diagrams, alongside the PRISMA guidelines, can (i) facilitate reporting of the quality 




Systematic review and meta-analysis of experimental and observational studies which 
included at least one prescribing or clinical outcome of RDTs in hospital in-patients.  Sub-
group analysis was used to assess heterogeneity in summary effect estimates.  A Sankey 
diagram was then used to show the pattern and quality of evidenceon RDT outcomes. 
 
Results  
57 studies from 14 countries were included.  The introduction of RDTs did not significantly 
reduce in-hospital mortality (RR 0.83, 95% CI 0.60 - 1.15) or length of stay (weighted mean 
difference = -0.36, 95% CI -1.67 to 0.96).  There was high heterogeneity in outcomes.  
 
Conclusion  
There is no clear evidence that the routine use of RDTs for bacterial identification and 
antibiotic susceptibility testing improves clinical outcomes in hospital inpatients. Sankey 
diagrams may be a useful further way succinctly to present the pattern and quality of 
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The identification and synthesis of evidence on outcomes of interventions is a key step in 
systematic reviews, and a focus of methodological research in clinical epidemiology.(1) 
Selection – and selective reporting - of outcomes is also a major source of bias in primary 
studies and thus reviews, and can lead to overestimates of the effectiveness of interventions, 
and under-reporting of harms. It can also involve the reporting of outcomes that represent no 
clinical benefit to patients, and for this reason there is an increasing emphasis on the 
incorporation of patients‟ views into the development of outcome measures, as a way of 
ensuring the utility and credibility of trial findings: “Clinical trials are only as credible as 
their endpoints".(2) Guidance from the Cochrane Handbook is that reviewers should choose 
only outcomes that are critical or important to users of the review, such as patients, health 
professionals and policy makers, and outcome measures should be defined in advance.(3)  In 
a mature field, where there are many trials reporting on direct patient benefit, this often 
involves selecting and synthesising evidence on a narrow set of outcomes. However, in fields 
where new technologies are rapidly emerging, it may be more useful to incorporate a wider 
range of  outcomes, to help assess the claims being made about the balance of costs and 
benefits of the intervention, and to help make judgements (sometimes in the absence of 
patient-level outcomes) about the potential effects of the intervention, drawing on evidence 
from different parts of the care pathway.  
 
Synthesising and reporting on a heterogeneous and complex set of outcomes is challenging, 
however. Common approaches used in systematic reviews such as summary tables and forest 
plots often do not make full use of the data – for example, they cannot show clearly how 
different studies contribute to understanding how interventions work at different points along 
the care pathway. This is particularly the case for diagnostic tests related to antimicrobial 
resistance (AMR). Diagnostic test accuracy, but not clinical effectiveness, has often been 
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used to justify the routine use of these tests.(4–8) This is because it is difficult to perform 
meta-analysis using the evidence on diagnostic tests for three reasons: its relative paucity;(9) 
different proprietary technologies with different functions in the bacteriology care pathway; 
and different outcomes measured in each study.    
In the absence of a previous evidence synthesis, we undertook a systematic review and meta-
analysis of the evidence on whether RDTs for bacterial identification and antibiotic 
susceptibility testing confer clinical advantages over standard tests. We were aware in 
advance that the available evidence was likely to be heterogeneous and difficult-to-interpret, 
covering different RDT technologies, and using different definitions of the same outcome. 
For example, some tests have been described as “rapid” when they take 14 hours, while 
others are considered rapid when they take 15 minutes.  
 
We were also aware of a proliferation of different outcomes in studies, which may in itself be 
a reason why no previous systematic review exists. We therefore used a Sankey diagram as a 
way of presenting the current state of the evidence on RDTs in AMR and to show how much 
of the evidence can be robustly synthesised.(10) Sankey diagrams represent flows (e.g. flows 
of information, or of any property) within a process, in this case the review process. They are 
frequently used in industrial processes and in engineering.(10)  The overall aim of this paper, 
then, is to demonstrate, using the example of a new systematic review of RDTs, how Sankey 
diagrams, alongside the PRISMA guidelines, can (i) facilitate reporting of the quality of the 









(i) The systematic review: We conducted a comprehensive systematic review and meta-
analysis of the outcomes of introducing rapid molecular diagnostic tests for bacterial 
identification and antibiotic susceptibility testing, following PRISMA guidelines.(9) .  The 
systematic review aimed to synthesise the evidence on effectiveness of RDTs in terms of 
clinical and prescribing outcomes compared with standard care in acute hospitals. The 
technologies included in the review are: multiplex, real-time, and quantitative polymerase 
chain reaction (PCR); matrix-assisted laser desorption ionisation time-of-flight mass 
spectrometers (MALDI-TOF MS); peptide nucleic acid florescent in situ hybridisation; and 
rapid procalcitonin testing.  We registered our protocol on PROSPERO (CRD 
42017060566) in 2017. 
 
We searched (with no language restrictions) Ovid Medline [1950-2017], Ovid Embase [1947-
2017], PubMed [1950-2017], Web of Science [1970-2017], Open Grey [1997-2017] and 
Cochrane CENTRAL [1997-2017].  (see Appendix 1).  Our search was conducted in April 
2017 and updated in April 2018. Two reviewers double-screened 20,592 titles, 1,445 
abstracts and 319 full-text studies. We included 57 studies in our final analyses.   The Kappa 
statistic for inter-rater reliability of inclusion and exclusion decisions was 0.6 (95% CI 0.553 
to 0.648), indicating moderate agreement.(11) To deal with this moderate level of agreement, 
and to ensure that our review was as sensitive as possible, where reviewers differed in their 
inclusion criterion, we discussed the relevant title, abstract or full text article, and unless there 
was an explicit missed exclusion criterion we always erred on the side of inclusion.  
 
Inclusion/exclusion criteria 
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Eligible participants were adults and children admitted to, and treated within, an acute 
hospital. The intervention of interest was the change in clinical or antibiotic prescribing 
outcomes that could plausibly be associated with an introduction of RDTs into the hospital. 
The comparator(s)/control was current hospital practice without RDT, defined as use of either 
a manual or automated culture system (Table 1).  The primary clinical outcomes were length 
of stay (LOS) and mortality, and the primary antibiotic outcome was duration of antibiotic 
therapy. We allowed for the collection of any type of mortality outcome but made provision 
for separate (30-day and all-cause in-hospital) mortality meta-analyses. Secondary outcomes 
were: reported changes in antibiotic plan, time to treatment, and turnaround time. (Table 1) 
We extracted aggregate data from each included study on all outcomes of interest. We 
included both experimental and observational study designs, synthesised separately. 
Observational studies comprised prospective and retrospective cohort studies, quasi-
experimental studies and interrupted time series analyses. Risk of bias was assessed using the 
Effective Public Health Practice Project (EPHPP) toolkit for quantitative studies and is 
included in Table 1.(12)  
 
All statistical analyses were conducted in Stata 15.1.(13)  When medians and interquartile 
ranges were reported as effect estimates, we transposed these into means and standard 
deviations using the methods of Luo et al, and then conducted subgroup analyses to validate 
the methodology.(14) We grouped those RDTs that were intended to replace either manual or 
automated culture, thereby reducing analysis time in the laboratory.   
 
The principal summary effect estimates (summary measures) that were calculated were 
length of stay (mean difference), in-hospital mortality (risk ratio) and 30-day mortality (risk 
ratio).  Random effects meta-analysis was used due to the heterogeneous interventions and 
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settings of each included study.(3,15) Not all studies that were included in the narrative 
synthesis were included in the meta-analysis (See Table 1). Higgins‟ I
2
 was used to assess 
heterogeneity among outcomes in the meta-analyses.(15)  Egger‟s test was not appropriate to 
conduct since there were small (n<10) numbers of studies in each subgroup analysis.(3,16)  
 
(ii) The Sankey diagram: As there were many antibiotic stewardship outcomes of interest 
reported, but few studies reported the same outcomes of interest, we used a Sankey Diagram 
to show the outcomes of interest (number of papers included in the narrative synthesis), how 
those studies can be categorised into subgroups, the attrition on the review pathway from 
narrative synthesis to potential meta-analysis, and to provide methodological justification for 
the proportion of the overall evidence that is included in the final meta-analysis.  Our Sankey 
diagram was constructed in the free, open source, online tool SankeyMATIC (BETA) 
(sankeymatic.com).  The code for this tool is available on Github and builds on the open-
source infographic design language D3.  The tool allows users to: specify the number of 
flows (where flows are primary  studies) in and out between nodes (which are stages or points 
in the synthesis process); and specify the number of nodes. Flows can transfer between nodes, 
as they have done in our Sankey diagram. In our Sankey diagram, the width of the arrows is 
proportionate to the number of outcomes of interest. On the left, separate arrows connote the 
types of outcomes, and on the right is a list of reasons for evidence attrition or small numbers 
of studies in the meta-analysis.  
 
Results 
There were 57 studies included in the final review. The study selection process is summarised 
in Figure 1.  The included studies are summarised in Table 1 and fully described in Appendix 
A, online.  









































From:  Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 






Records identified from*: 
Databases (n = 6 ): 27,349 
Hand searching and expert 
consultaiton: 18 
Records removed before 
screening: 
Duplicate records removed  






(n = 19,147) 
Abstracts screened 
(n = 1445) 
Abstracts excluded 
(n = 1126 ) 
Reports assessed for eligibility 
(n = 319 ) 
261 Reports excluded: 
No clinical or prescribing 
outcomes reported in results 
(n = 168) 
Duplicate not picked up 
earlier (n =2 ) 
Erratum (n = 1) 
Japanese, Korean, german 
(n=5) 
Conference/poster abstract 
(n = 81 ) 
Systematic review (n=2) 
Not a rapid diagnostic (n=3) 
 
Studies included in review 
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Table 1. Sample of included studies and extracted characteristics in the narrative systematic 
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Of the 57 included studies, 13 met the criteria for inclusion in a meta-analysis of length of 
stay, eight for meta-analysis of 30-day mortality, and seven for meta-analysis of in-hospital 
all-cause mortality.  There were 30 antibiotic stewardship outcomes reported in 17 studies, 
but the lack of overlap of reported outcomes among studies made meta-analysis of these  
outcomes impossible. 
 
Patients whose tests were undertaken using RDTs stayed in hospital an average of 0.36 (95% 
CI -1.67, 0.96, n.s.) days less  than patients whose samples were processed using 
conventional methods in experimental studies, and 2.52 fewer days than patients whose 
samples were processed using conventional methods in the observational studies (95% CI -
3.88 to -1.17).  This can be seen in Figure 2. We conducted separate meta-analyses for 
experimental and observational studies. There was no significant heterogeneity among the 
RCTs (I
2
= 0%, p=0.532) and moderate heterogeneity among the observational studies (I
2
= 
37.9%, p=0.106). (17) 
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Figure 3 Meta-analysis of studies reporting 30-day mortality 
 
Figure 4 Meta-analysis of studies reporting in-hospital mortality 
While 18 studies reported mortality measures, only eight reported 30-day mortality (Figure 3) 
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and seven reported all-cause in-hospital mortality (Figure 4). The overall risk ratio for 30-day 
mortality was 0.90 (95% CI 0.59-1.35) for experimental studies, and 0.59 (95% CI 0.41-0.77) 
for the observational studies. Among the experimental studies, there was no significant 
difference in 30-day mortality between RDTs and conventional methods. By contrast, there 
was a strong reduction in mortality in the observational studies, although, as with the length 
of stay analysis, many observational studies included ASPs in their post-test timeframes, 
something that the RCTs controlled for by either not including them or by including a third-
arm in the trial.   
 
The random effects summary estimate of the effect of RDTs on in-hospital mortality was 
0.83 (95% confidence interval 0.60 to 1.15; n.s.). When these seven studies were combined 
for random effects meta-analysis, heterogeneity was low (X
2
=7.14) and the variation in the 
risk ratio attributable to heterogeneity was also low (I
2
=16.0%, p=0.308).  
 
In 17 studies, there were 30 different antibiotic stewardship outcomes included, such as „time 
to first appropriate (de)escalation‟, „prevention of unnecessary vancomycin‟, „time from 
positive result to isolation precautions‟, „appropriate antibiotic therapy for bacteraemic 
patients‟.  Many differences were reported as being statistically significant but no meta-
analysis was possible due to the high degree of heterogeneity. A summary of these outcomes 
is included in supplementary file 1.  
 
Given the small numbers of included studies, there were few opportunities for subgroup 
analysis. However, we were able to assess the impact of study characteristics on the length of 
stay summary effect estimates in two ways: by comparing summary effect sizes in moderate 
and lower quality studies; and by assessing the impact of the statistical transformation of the 
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reported length of stay from median and range, to mean and standard deviation. In neither 
case did the subgroup effect estimates differ statistically from the aggregate effect estimates.  
 
The definitions of „turnaround times‟, „reporting times‟ and „time to result‟, which are the 
most frequently cited improvements attributed to RDTs, overlapped and varied enormously 
(See Figure 5). While the stylised pathway in Figure 5 neither captures the nuances of the 
entire care pathway, nor indicates that some activities can be undertaken concurrently, we 
validated it with a consultant clinical microbiologist, who judged it to be an appropriate 
general description of the key steps in the process. The most commonly reported (11/36) 
timed pathway segment was from “sample-to-report”. Many studies reported on multiple 
slices of time in the care pathway, however, only one study reported on the effect of RDT use 
from patient admission through to isolation (see Figure 5).(18) One further study reported on 
the effect of RDT use from patient admission through to the clinician‟s receipt of an 
antibiotic susceptibility test report AST (and consequent ability to modify therapy, if 
appropriate).(19)  
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Figure 5 Bacteriological care pathway mapped to definitions of turnaround time and time-to-result. Where 0-9 represent a 
simplified bacteriological care pathway, as annotated below 
 
 
(ii) The use of the Sankey diagram to synthesise the findings 
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Figure 6 Sankey Diagram with outcomes of interest arranged down the left-hand side followed by the number of  studies 
included in narrative synthesis (outcome: studies).  Down the right-hand side of the diagram, four explanations for evidence 
attrition or small meta-analyses, and how many studies’ data fell into this category (explanation: studies). Flow from left to 
right: follow how the outcomes of interest are narrowed into smaller and smaller groups until they can be described by one 
of the four reasons. Read together with the description of the results, this diagram visually demonstrates why certain meta-
analyses were small (such as mortality), why certain meta-analyses could not be undertaken (such as for stewardship; and 





The Sankey diagram (Figure 6) helps the reader to interrogate the body of evidence in the 
review at a glance. For example, we have not meta-analysed antibiotic stewardship outcomes. 
The reader would know this by reading the entire paper, but the Sankey diagram summarises 
the point; there are 30 antibiotic stewardship outcomes (“outcomes of interest” in the 
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diagram) reported in 17 studies. The third flow on the diagram also shows the number of 
studies (17), the number of definitions (30), and the reason why they could not be combined 
quantitatively (different endpoints) within one flow.  The data behind the Sankey, and more 
information about how to read it, is represented in Table 2. This table could be adapted for 
any review that aims to provide more detail about the exclusion of reported quantitative data 




Table 2 Table explaining the Sankey Diagram. Explanation of columns from left to right: the outcome of interest, the number 
of studies reporting the outcome, whether studies were included or excluded in meta-analysis and why, the number of those 
studies, whether subgroup or statistical variation further divided the studies, the number of studies in each subgroup, and 





















Length of stay 25 
Excluded  12 
n/a n/a Not enough to 
aggregate  
Included RCTs 3 
Mean/SD 2 Statistical 
variation* 






Mean/SD 7 Statistical 
variation* 












30-day 8 Different 
endpoints* 
In-hospital 7 Different 
endpoints* 
28-day 4 Different 
endpoints** 
7-day 1 Different 
endpoints** 
14-day 2 Different 
endpoints** 





Turnaround time 19 Excluded 19 Definitions 36 Heterogeneous 
definitions*** 
*leading to small meta-analyses and large confidence intervals 
**Not enough of the same outcome to aggregate  
***Not enough of the same concept to aggregate 
 






Overview of diagnostic testing  
Appropriate antibiotic therapy is one of the most important aspects of the successful 
treatment of bacterial infections. RDTs for bacterial identification and antibiotic 
susceptibility have been developed to try to reduce the time to appropriate antibiotic therapy, 
shorten length of stay and improve patient outcomes such as mortality. However, our 
synthesis suggests that the introduction of RDTs for bacterial identification and antibiotic 
susceptibility testing is unlikely to lead to lower in-hospital mortality or reductions in length 
of stay. Moreover, while the available observational studies do suggest a significant reduction 
in 30-day mortality and length of stay, these studies are heterogeneous, have methodological 
flaws. 
 
The Sankey diagram revealed that there is great heterogeneity even in the mortality outcomes 
reported, in spite of the recent emphasis on the need for appropriate outcome selection for 
evaluation of antibiotic therapies (highly relevant to the evaluation of RDTs for antibiotic 
susceptibility and resistance) and the emerging consensus towards greater use of core 
outcomes, in particular 28-day, 30-day, or in-hospital mortality.(20) We suggest that Sankey 
diagrams can be a valuable aid to transparency in systematic reviews, particularly as a way of 
showing why particular studies and study outcomes become excluded from the final set of 
analyses.  They can also allow for comparisons to be made across review topics; though the 
diagram does not show this directly, certain issues such as whether there are structural biases 
leading to more evidence attrition in certain fields of research, or with industry-funded 
research for example, could begin to be answered with diagrams such as these. It can also 
address issues of „research waste‟. The diagram shows the amount of evidence that is wasted 
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because it cannot easily be included in synthesis processes and consequently is left out, or 
only included in narrative syntheses, which are traditionally given less evidentiary „weight‟ 
than even a small meta-analysis. There are resource and ethical issues associated with this, 
and the variability between studies may encourage the production of misleading summaries 
of the evidence, prevent the production of regular systematic reviews of that evidence, and 
and encourage and cherry-picking of positive outcomes. 
 
The review itself highlighted major problems in the RDT evidence base.  One is that the 
primary studies are often underpowered. Neither bloodstream infections nor resistant 
bacterial infections are particularly rare, yet sample sizes are surprisingly small throughout all 
included studies.  Egger‟s test for small study effect is only recommended with 20 or more 
studies, for example, but the largest subgroup in this review was 10 studies. A further 
problem is the lack of consistency and clarity in definitions of outcomes  - it is often unclear 
which parts of the care pathway are being reported when the term „turnaround time‟ is used in 
primary studies, and frequently there is no explanation as to why a particular part of the 
pathway has been chosen, and whether it was chosen a priori.  This lack of standard 
definition, measurement and reporting of these outcomes makes it difficult for service 
providers and policy makers to use evidence to decide whether to invest in RDTs in general 
and, in turn, which to purchase.  It also makes it impossible to synthesise the evidence 
comprehensively, as shown graphically in the Sankey diagram. Standardising these 
definitions would help. For example, „turnaround time‟ is most useful to clinical 
commissioners if defined as the time from patient sampling to results being acted upon by 
clinicians, as this represents the full care pathway likely to be modified by RDTs.  To this end 
Table 3 proposes some definitions to help standardise and clarify these outcomes for future 
studies (Table 3). 





Table 3: Suggested definitions for diagnostic pathway outcomes in RDT evaluations  
Turnaround time The time from collecting a sample from a patient to a laboratory result 
being actioned by a clinical decision-maker  
Time to result  The time from collecting a sample from a patient to the result being 
released by the laboratory  
Running time The active time of a technology from sample being inserted/inputted 




There are several limitations to this study. First, it proved impossible to synthesise the 
evidence of the effects of RDTs on turnaround time or other antibiotic stewardship outcomes 
because of the lack of standard definitions of reported outcomes across studies, as shown in 
the Sankey diagram. Antibiotic stewardship outcomes represent the main positive impact of 
RDTs according to some commentators, but this remains a controversial assertion given the 
limitations in the evidence.  Also, while experimental studies sometimes incorporated 
antibiotic stewardship as a discrete third arm in trials so as to disaggregate the effect of the 
rapid diagnostic test from the effect of the stewardship intervention, many of the pre-post 
quasi-experimental studies bundled antibiotic stewardship programmes with the addition of a 
novel diagnostic test. It remains possible that bundling stewardship measures with the 
diagnostic test may be confounding the impact of the diagnostic intervention. This would 
reflect previous research in this area.(21–26)  We therefore suggest that care should be taken 
in future studies not to attribute an impact to diagnostics where the impact could have come 
from improved stewardship measures.   
Given the small number of studies in the area as a whole, there is a need for better evidence 
on the in-hospital impact of RDTs. Some mathematical modelling studies have endorsed 
intra-hospital infections averted as a useful metric, but the advent of whole genome 
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sequencing could be employed alongside RDTs to validate attempts to capture this outcome 
in real-world evaluations. If rapid diagnostics are to demonstrate clinical value, it is likely to 
be in terms of their effects on such indirect outcomes. 
 
Conclusion 
We recommend that future systematic reviews of similar diagnostic technologies consider 
adopting a health services research perspective, in line with the current review, which takes 
account not just of final outcomes (mortality; length of stay) but also intermediate outcomes 
(appropriate antibiotic therapy).  Such an approach allows a wider range of the available 
evidence to be synthesised to help understand the clinical and health services effects of new 
technologies destined for the hospital laboratory  This review shows that there is insufficient 
high-quality evidence to conclude that these diagnostic technologies reduce length of stay or 
mortality.  This is likely to be because of presumptive treatments and the complexity of the 
care pathway. Sankey diagrams can help to show how the range of evidence is able to 
contribute, or not, to a review‟s conclusions. They may be of particular value in improving 
the transparency of systematic reviews of complex interventions where the evidence is 
disparate and assessing its adequacy. Sankey diagrams may also be of use when a review 
covers many different outcomes and outcome definitions, and is only partially amenable to 
meta-analysis. 
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Strengths and limitations of this study:  
Strengths 
This is the first systematic review and MA of the effectiveness of RDTs for bacterial 
identification and antibiotic susceptibility testing which shows that, despite their 
widespread use and claims about their value, they do not appear to be effective 
We developed a novel method to identify, group, and analyse included studies in a 
systematic review using a Sankey diagram 
Sankey diagrams can help compare patterns of methodological quality and variation in 
outcomes within primary studies across sectors and topics within a review.  They provide 
a visual way of identifying methodological concerns in the evidence included in 
systematic reviews. 
We demonstrated this technique in an area where systematic review and meta-analysis is 
underused, namely the clinical effectiveness of rapid diagnostic tests for bacterial 
identification and antibiotic susceptibility testing.  
Limitations 
While there appears to be evidence of reporting bias (publication bias, small study 
effects), the paucity of studies included in our systematic review means that Egger‟s test 
is underpowered so the influence of publication bias on the summary estimates is difficult 
to determine.  
There is a lack of standard terminology used to report „turnaround time‟ and standard 
antibiotic escalation and de-escalation outcomes of interest; in addition to the greater use 
of Sankey diagrams we also recommend standardised definitions of, and greater care in, 
selecting endpoints.  
 
Data sharing 
Reasonable requests for data can be requested by email from the corresponding author.  
Patient and public involvement 
Patients and the public were not involved in conducting the systematic review and meta-
analysis, though two PPI representatives reviewed the research question at the beginning of 
the research process, and also aided us in the development of plain English summaries for 
public engagement work related to this research.   
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